Driving value creation through medical affairs in China

Summary:

After more than three decades of fast economic growth, China has entered the “new normal” stage, marked by a moderate and stable domestic GDP growth rate. Healthcare has been elevated to a national level agenda by the current leadership with the releasing of “China Health 2030”.

In addition, “Made in China 2025” (shown in Figure 1) has also demonstrated Chinese government’s mission to foster innovation while continuing to enhance drug safety and improve healthcare service quality.

Download '.pdf' Format of the whitepaper.

Download Whitepapers
Latest Issue
Get instant
access to our latest e-book
Thermo Fisher Scientific - Chromatography Solutions Eppendorf - Discover the Flow Meco - 90 years